Former Senior Vice President, General Counsel and Secretary · LIGAND PHARMACEUTICALS INC (LGND)

Charles Berkman

A named executive officer of LIGAND PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$2,433,437

Salary $396,920Stock awards $1,200,811

FY2021: $2,980,948

7th of 7 named executive officers at Ligand Pharmaceuticals by FY2022 total.

7 named officers on file for LIGAND PHARMACEUTICALS, FY2022

Charles Berkman’s pay file — $29

  • 7 fiscal years of pay, line by line
  • 15 equity grants, each cited to its filing
  • LGND’s disclosed peer group of 44 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how LIGAND PHARMACEUTICALS’s whole pay program stands against its peers

  • LIGAND PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LGND→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 20, 2023 (DEF 14A).

Free

Get Charles Berkman’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Charles Berkman compensation by year

LIGAND PHARMACEUTICALS Summary Compensation Table · all 7 fiscal years held
In US dollars, as LIGAND PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020FY2021FY2022
Salary$329,167$362,812$402,500$427,620$441,917$451,682$396,920
Bonus$0$0$0$0$0$0$0
Stock awards$376,275$466,461$623,961$733,290$644,168$1,665,811$1,200,811
Option awards$452,035$486,593$533,547$722,777$675,820$649,308$823,556
Non-equity incentive$136,350$174,150$177,100$136,933$176,767$203,257$0
Pension and deferred compensation$0$0$0$0$0$0$0
All other$6,343$8,803$6,471$6,547$6,180$10,890$12,150
Total$1,300,170$1,498,819$1,743,579$2,027,167$1,944,852$2,980,948$2,433,437

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: LIGAND PHARMACEUTICALS INC DEF 14A filed April 20, 2023, accession 0000886163-23-000018, and prior-year filings.

How this page was built: the LIGAND PHARMACEUTICALS INC filed document, accession 0000886163-23-000018. Every figure is read from that document and cited to the page and table it appears in. Filed April 20, 2023.

$1.3M
$1.5M
$1.7M
$2.0M
$1.9M
$3.0M
$2.4M
FY16
FY17
FY18
FY19
FY20
FY21
FY22
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU7,188$480,158—
Option532—$68.74
Option4,385—$55.75
Option3,290—$103.42

Per the Outstanding Equity Awards at Fiscal Year-End table in LIGAND PHARMACEUTICALS INC's FY2022 proxy; value at the fiscal year-end close, as the company printed it.

LIGAND PHARMACEUTICALS’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
John HigginsFormer Chief Executive Officer$16,764,990
Matthew KorenbergPresident and Chief Operating Officer$6,542,545
Todd DavisChief Executive Officer$5,195,169
Matthew FoehrFormer President and Chief Operating Officer$4,007,766
Tavo EspinozaChief Financial Officer$3,272,252
Andrew ReardonChief Legal Officer and Secretary$3,007,654
Charles Berkman · this pageFormer Senior Vice President, General Counsel and Secretary$2,433,437

The full LIGAND PHARMACEUTICALS compensation record

free company brief

This page is one person within LIGAND PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the LIGAND PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are LIGAND PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Charles Berkman's compensation dossier · One-time report. No refunds.